Recently, Sina Finance unveiled the "2025 China Corporate ESG Top 100" list. Shijiazhuang Yiling Pharmaceutical Co., Ltd. successfully earned a spot on this prestigious ranking due to its systematic and outstanding practices in the environmental, social, and governance (ESG) fields.
After over 30 years of steady development, Yiling Pharmaceutical has established a unique, integrated operational model encompassing "theory-clinical trials-new drugs-industry-education," creating a solid foundation for its ESG initiatives. During this period, the company has undertaken more than 60 national and provincial-level scientific research projects and has been honored with six National Science and Technology Awards. It has successfully developed 17 innovative patented traditional Chinese medicines targeting major disease areas, including cardiovascular and cerebrovascular diseases, respiratory illnesses, cancer, diabetes, neurological disorders, and urological diseases. The company has achieved significant breakthroughs and important results across its core business segments, such as scientific TCM, chemical and biological drugs, and the health industry.
Yiling Pharmaceutical consistently integrates ESG principles deeply into its corporate strategy and daily operations. In environmental protection, the company actively implements a green development strategy. Through measures like promoting energy conservation and emissions reduction, constructing green factories, and innovating green technologies, it contributes to a low-carbon society, demonstrating the environmental responsibility of a modern pharmaceutical enterprise. In the social responsibility domain, Yiling Pharma leverages its professional expertise as a pharmaceutical company. It is not only committed to researching and producing high-quality medicines to alleviate patient suffering but also actively participates in public welfare. The company makes positive contributions through initiatives like donating to support education, aiding rural revitalization, and providing free medical services and medicines, highlighting its strong sense of social responsibility. At the corporate governance level, Yiling Pharmaceutical continuously refines its modern enterprise system, strengthens compliant operations, and emphasizes the protection of shareholder rights. Through a sound governance structure and transparent information disclosure, it has laid a solid foundation for sustainable development.
The list is based on Sina Finance's ESG rating system, which evaluates over 5,000 A-share listed companies and mainland enterprises listed in Hong Kong. It employs 18 sets of industry-specific ESG evaluation models to conduct a comprehensive and quantitative assessment of corporate ESG performance. The rating system incorporates more than 150 ESG indicators, drawing data from corporate sustainability reports and third-party sources, to arrive at a comprehensive ESG rating score for each company. The top 100 ranked companies are selected for the "Listed Companies Annual ESG Top 100" ranking.
